RE:RE:TH1902 effects on Progranulin The competitive effect of TH1902 on sortilin receptors, versus progranulin is too short in my view to have any meaningful effect on cancer proliferation. Half-life of TH1902 is relatively short, few hours, so soon as it is no longer in the bloodstream, progranulin is free to bind sortilin again. This MOA would possibly work only with long acting formulation of the peptide (without docetaxel) or with daily injections. We are far from that at this point. Let's see proof of concept of the PDC first, if so, it will open alot of possibilities.
Wino115 wrote: I think you've stumbled upon one of the possible methods of action that both Spartrap and Qwerty are hoping is one of the 3 MOAs for TH1902. It may also be part of the disruption of vascular mimicry that they have seen in vitro. That is one of the more intriguing possibilities of the peptide and whole platform. If they can uncover that it does work beneficially in three different ways, it's not just a home run, it's a grand slam....or for our hockey-heads, a hat-trick!
jeffm34 wrote: If Th1902 can target and kill cancer cells that have Sortilin, it should also have positive effects on cancer progression by inhibiting Progranulin.
"Progranulin is involved in biological processes such as wound healing, inflammation and cancer progression. Progranulin and its receptor sortilin are known to be highly expressed in subgroups of breast cancer and are further associated with a clinically aggressive phenotype."